Trial Search Results

A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)

Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Gary Steinberg

Collaborator: California Institute for Regenerative Medicine (CIRM)

Stanford Investigator(s):


  • Biological: Neural Stem Cells


Phase 1/Phase 2


Inclusion Criteria:

   - Age 18 - 75 years

   - History of ischemic subcortical stroke in the middle cerebral artery and/or
   lenticulostriate artery 6 to 60 months from time of stroke

   - Ability of subject to understand and provide written Informed Consent

   - Willing to take tacrolimus (Prograf) 2 days before and for 2 months after transplant

Exclusion Criteria:

   - Stroke lesion less than 1 cubic centimeter or greater than 100 cubic centimeters
   measured by MRI

   - Index stroke is lacunar infarct less than 1 year old

   - History or presence of any major neurological disease

   - History of active cancer other than basal or squamous cell skin cancers

   - History of seizures

   - Pregnant or breast-feeding

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Clinical Research Coordinator